Protocol Study Chair Information for Patients and Families Information for Health Professionals Industry/Foundation Support NCI Trial ID
PBTC-045:
A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs
Eugene Hwang, MD
Children’s National Medical Center
111 Michigan Ave, NS
Washington, DC 20010
Telephone: 202-476-5046
Fax: 202-476-4304
Email: [email protected]
Summary for Patients and Families Abstract for Health Professionals NCT02359565
PBTC-048:
Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Stewart Goldman, MD
Phoenix Children’s Hospital
1919 E. Thomas Road
Phoenix, AZ 85016
Phone: (602) 933-5468
Email: [email protected]
Summary for Patients and Families Abstract for Health Professionals
  • Novocure
NCT03033992
PBTC-049:
A Phase I study of Savolitinib in Recurrent, Progressive, or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS tumors harboring MET aberrations
Ralph Salloum, MD
Cincinnati Children’s Hospital Medical Center
3333 Burnett Avenue
Cincinnati, OH, 45229
Phone: (513) 803-1126
Fax: (513) 636-5349
Email: [email protected]
Summary for Patients and Families Abstract for Health Professionals NCT03598244
PBTC-051:
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Ira Dunkel, MD
Memorial Sloan Kettering Cancer Center
Department of Pediatrics
Howard 1102
New York, NY 10065
Phone: (212) 639-2153
Fax: (212) 717-3239
Email: [email protected]
Summary for Patients and Families Abstract for Health Professionals
  • Solving Kids’ Cancer
  • Kamen Brain Tumor Foundation
  • Isabella Rose Romano Foundation
  • TeamConnor Childhood Cancer Foundation
  • Apexigen
NCT03389802
PBTC-053:
A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma
Ralph Salloum, MD
Cincinnati Children’s Hospital Medical Center
3333 Burnett Avenue
Cincinnati, OH, 45229
Phone: (513) 803-1126
Fax: (513) 636-5349
Email: [email protected]
Summary for Patients and Families Abstract for Health Professionals
  • Senhwa
NCI-2019-00180
PBTC-055:
Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults
Lindsey Hoffman, DO
Phoenix Children's Hospital
1919 E Thomas Rd
Phoenix, AZ 85016
Phone: (602) 933-0920
Fax: (602) 933-2492
Email: [email protected]
Abstract for Health Professionals
  • Pediatric Brain Tumor Foundation
  • Novartis
NCI-2019-06216
PBTC-056:
A Phase I Study Of The Adam-10 Inhibitor, INCB7839 In Children With Recurrent/Progressive High-Grade Gliomas To Target Microenvironmental Neuroligin-3
Michelle Monje, MD PhD
Stanford University and Lucile Packard Children's Hospital
750 Welch Road, Suite 317
Palo Alto, CA 94304
Phone: (650) 721-5750
Fax: (650) 723-7299
Email: [email protected]
Summary for Patients and Families Abstract for Health Professionals
  • Incyte
NCT04295759
PBTC-058:
Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma
Matthias Karajannis, MD, MS
Memorial Sloan Kettering Cancer Center
1275 York Avenue, Box 234
New York, NY 10065
Phone: (212) 639-3171
Fax: (212) 717-3239
Email: [email protected]
Summary for Patients and Families Abstract for Health Professionals
  • Pediatric Brain Tumor Consortium Foundation (PBTCF)
  • Y-mAbs
NCT04743661
PBTC-059:
Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma
Meenakshi Hegde, MD
Texas Children’s Hospital
1102 Bates Ave. Suite 1770
Houston, TX 77030
Phone: (832) 824-4840
Fax: (832) 825-4732
Email: [email protected]
  • Pediatric Brain Tumor Consortium Foundation (PBTCF)
  • Children’s Access to Regenerative Medicine (CARMIT)
  • Cancer Prevention and Research Institute of Texas (CPRIT)
NCT04903080
PBTC-060:
A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Clare J Twist, MD
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14623
Phone: (716) 845-2333
Fax: (716) 845-8003
Email: [email protected]
Abstract for Health Professionals
  • Roswell Park Alliance Foundation
  • MimiVax, LLC
NCT04978727
Protocol Study Chair Information for Health Professionals PubMed ID
PBTC-001:
Pilot Study of Systemic and Intrathecal Chemotherapy followed by Conformal Radiation for Infants with Embryonal Intracranial Central Nervous System Tumors
Susan Blaney, MD
Abstract for Health Professionals PMC3529096
PBTC-002:
A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors
Mark W. Kieran, MD, PhD
Abstract for Health Professionals PMC2775441
PBTC-003:
Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with Refractory or Recurrent Brain Tumors
Mark W. Kieran, MD, PhD
Abstract for Health Professionals PMID17634493
PBTC-004:
Phase I Study of Intrathecal SpartajectTM-Busulfan in Children with Neoplastic Meningitis
Sri Gururangan, MRCP (UK)
Abstract for Health Professionals PMID16533779
PBTC-005:
Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors
Amar J. Gajjar, MD
Abstract for Health Professionals PMID18006772
PBTC-006:
A Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor Prognosis Brainstem Gliomas and Recurrent Intracranial Malignant Gliomas
Ian F. Pollack, MD
Abstract for Health Professionals PMC1871662
PBTC-007:
A Phase I/II Trial of ZD1839 (IressaTM) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II limited to Brain Stem Tumors
J. Russell Geyer, MD
Abstract for Health Professionals PMC2988095
PBTC-009:
Phase I Trial of GLIADEL® and O6-Benzylguanine in Pediatric Patients with Recurrent Malignant Gliomas
Ian F. Pollack, MD
Abstract for Health Professionals  
PBTC-010:
A Phase II Study of Oxaliplatin in Children with Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors
Maryam Fouladi, MD
Abstract for Health Professionals PMID17019740
PBTC-011C:
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusion in Pediatric Patients with Recurrent Malignant Glioma
Anuradha Banerjee, MD, MPH
Abstract for Health Professionals  
PBTC-012:
Phase I Study of Cilengitide (EMD 121974) in Children with Refractory Brain Tumors
Tobey MacDonald, MD
Abstract for Health Professionals PMID18281665
PBTC-013:
A Phase I/II Study of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-a and a Mutated Form of the Pseudomonas Exotoxin Termed PE38 (TP-38) in Pediatric Patients with Recurrent or Progressive Supratentorial High Grade Gliomas
Roger Packer, MD
Abstract for Health Professionals  
PBTC-014:
Phase I/II Trial of Zarnestra and XRT in Pediatric Patients with Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas
Daphne Haas-Kogan, MD
Abstract for Health Professionals PMC2563056
PBTC-015:
A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients with Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors
Kathy Warren, MD
Abstract for Health Professionals PMC3518022
PBTC-016:
A Phase I, Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma
Maryam Fouladi, MD
Abstract for Health Professionals PMC2953974
PBTC-017:
Phase I Study of CLORETAZINE ™ (VNP4010M) in Children with Recurrent, Progressive or Refractory Primary Brain Tumors
Sri Gururangan, MRCP (UK)
Abstract for Health Professionals PMID18281546
PBTC-018:
A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors
Kathy Warren, MD
Abstract for Health Professionals PMC3056466
PBTC-019:
A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children with Neoplastic Meningitis
Susan Blaney, MD
Abstract for Health Professionals PMC3573253
PBTC-020:
A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumor
Mark Kieran, MD, PhD
Abstract for Health Professionals PMC4561207
PBTC-021:
A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas
Susan Blaney, MD
Abstract for Health Professionals PMC3661085
PBTC-022:
Phase II study of Bevacizumab plus Irinotecan (CamptosarTM) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
Sri Gururangan, MRCP (UK)
Abstract for Health Professionals PMC2903337
PBTC-023:
Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents with Refractory Primary CNS Tumors
Susan Blaney, MD
Abstract for Health Professionals PMC4288513
PBTC-024:
A Phase I Study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies
Maryam Fouladi, MD
Abstract for Health Professionals PMC3179253
PBTC-025:
A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449
Amar J. Gajjar, MD
Abstract for Health Professionals PMC3856244
PBTC-025B:
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma
Amar J. Gajjar, MD
Abstract for Health Professionals PMC4534527
PBTC-026:
A Feasibility Study of SAHA combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
Sarah Leary, MD
Abstract for Health Professionals PMID34935967
PBTC-027:
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors
Jack Su, MD
Abstract for Health Professionals PMC4232081
PBTC-029B:
A Phase I and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Jason Fangusaro, MD
Abstract for Health Professionals  
PBTC-030:
A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas
Lindsay Kilburn, MD
Abstract for Health Professionals PMC5774861
PBTC-031:
Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients with Refractory or Recurrent CNS Tumors
Roger Packer, MD
Abstract for Health Professionals PMC4330963
PBTC-032:
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma
Amar J. Gajjar, MD
Abstract for Health Professionals PMC4534527
PBTC-033:
A Phase I/ II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)
Patricia A. Baxter, MD
Abstract for Health Professionals PMC7283021
PBTC-037:
A phase I study of intratumoral/peritumoral herpes simplex virus-1 mutant HSV1716 in patients with refractory or recurrent high grade gliomas (HGG)
Mariko DeWire, MD
Abstract for Health Professionals  
PBTC-039:
A Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma
Stewart Goldman, MD
Abstract for Health Professionals PMC7690365
PBTC-041:
A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors
Stewart Goldman, MD
Abstract for Health Professionals PMC4999001
PBTC-042:
Phase I study of CDK 4-6 inhibitor PD- 0332991 (palbociclib; IBRANCE) in children with recurrent, progressive or refractory central nervous system tumors
David Van Mater, MD, PhD
Abstract for Health Professionals PMC8414988
PBTC-043:
A Phase I Trial of Pomalidomide for children with recurrent, progressive or refractory CNS tumors
Jason Fangusaro, MD
Abstract for Health Professionals PMC7757731
PBTC-047:
A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
Michelle Monje, MD PhD
Abstract for Health Professionals
PBTC-050:
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children with Recurrent or Refractory Malignant Brain Tumors
Mariko DeWire-Schottmiller, MD
Abstract for Health Professionals PMC8132306